Light is a powerful pharmacological tool that can be used to selectively activate a photo-reactive drug in a specific location. This method, called photodynamic therapy, has been used successfully as a treatment for a variety of cancers including lung, pancreatic, esophageal, and skin cancers. However, most current photodynamic therapies require ultra-violet light, which has poor tissue penetration depths and can severely damage cells. This technology is a class of ruthenium-based tethers that can bind compounds and release them when exposed to visible or infrared light. It can be used to deliver a variety of biologically active molecules, including neurotransmitters, locally and selectively.
In addition to being far more biocompatible and having longer penetration depths, visible and infrared light sources are also far more cost effective than high-energy ultraviolet light. This technology relies on the unique photoactivity of ruthenium-bipyridal complexes, whose structures change dramatically upon activation with low-energy visible and, in some cases, infrared light. These ruthenium-tethers can potentially be used in combination with any molecule that contains an amino functionality that is required for its bioactivity.
This technology has been demonstrated on a number of tether-neurotransmitter complexes, and it has been utilized in vivo to map receptors for the neurotransmitter GABA. It has also been used to photoactivate neurons and dendritic spines with single-cell precision.
Tech Ventures Reference: IR M09-102